Hugel Obtains Colombian Approval for Three Types of Lidocaine HA Fillers

[Asia Economy Reporter Hyungsoo Park] Hugel is continuing its aggressive approach toward the global HA filler market.

On the 7th, Hugel announced that it had obtained product approval from the Colombian Food and Drug Regulatory Authority (INVIMA) for three types of ‘Hyalsense Plus’ products last month. Previously, in 2015, Hugel had acquired product approval in Colombia for three products in the ‘Hyalsense’ series.

The approved products are ▲ Hyalsense Fine Plus ▲ Hyalsense Ultra Plus ▲ Hyalsense Sub-Q Plus. Hugel has expanded the range of choices by launching three products with different viscosities to achieve high elasticity while providing natural volume according to the purpose and area of the procedure.

All three products contain the local anesthetic ‘lidocaine,’ which reduces patient pain during procedures.

Based on the approval, Hugel plans to strengthen its local market dominance of its HA filler products. Currently, the Colombian HA filler market is approximately 54,000 syringes annually as of 2020, with 85% of the market occupied by lidocaine-containing products.

The company aims to achieve a 20% market share in the local HA filler market by 2025 along with the Hyalsense series. To this end, it is conducting online and offline workshops and training programs with its local partner, Abbott.

A Hugel representative stated, "Colombia is a highly promising market expected to grow annually by 8-12% until 2025," and added, "Along with competitive product pricing, we plan to rapidly expand our competitiveness through the synergy of the ‘Hyalsense’ series, which has already successfully established itself in the local market, and our botulinum toxin product ‘Magnion.’"